Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study

An oncolytic, nonpathogenic ECHO-7 virus adapted for melanoma that has not been genetically modified (Rigvir) is approved and registered for virotherapy, an active and specific immunotherapy, in Latvia since 2004. The present retrospective study was carried out to determine the effectiveness of Rigv...

Descripción completa

Detalles Bibliográficos
Autores principales: Doniņa, Simona, Strēle, Ieva, Proboka, Guna, Auziņš, Jurgis, Alberts, Pēteris, Jonsson, Björn, Venskus, Dite, Muceniece, Aina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
ORIGINAL ARTICLES: Clinical research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560272/
https://www.ncbi.nlm.nih.gov/pubmed/26193376
http://dx.doi.org/10.1097/CMR.0000000000000180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560272/
https://www.ncbi.nlm.nih.gov/pubmed/26193376
http://dx.doi.org/10.1097/CMR.0000000000000180

Ejemplares similares